Stage-Wise Management of Breast Carcinoma

General Principles

• The National Comprehensive Cancer Network recommends breast cancer treatment be fundamentally organized into four distinct categories based on stage: Stage 0 (noninvasive disease), Stages I-II and operable IIIA (early/operable locoregional disease), Stage IIIB-IIIC and inoperable IIIA (inoperable locoregional disease), and Stage IV (metastatic disease) 1, 2

Stage 0: Pure Noninvasive Carcinomas

• The National Comprehensive Cancer Network suggests performing bilateral diagnostic mammography to identify extent and multifocality, followed by pathology review to exclude invasive disease in patients with ductal carcinoma in situ (DCIS) 1
• Observation alone is the preferred management strategy after pathology review and bilateral mammography for patients with lobular carcinoma in situ (LCIS) 1

Stage I, IIA, IIB, and Operable T3N1M0: Early/Operable Locoregional Disease

• Complete staging includes history/physical examination, CBC with platelets, liver function tests, bilateral diagnostic mammography, breast ultrasound as needed, pathology review with ER/PR/HER2 determination, as recommended by the National Comprehensive Cancer Network 2, 3
• The National Comprehensive Cancer Network recommends performing genetic counseling if high-risk features are present 2
• Additional imaging (bone scan, abdominal CT/ultrasound/MRI) is optional unless symptoms or abnormal labs suggest metastatic disease, as suggested by the National Comprehensive Cancer Network 2, 4

Surgical Phase

• The American Cancer Society states that two equivalent options exist with similar survival rates: breast-conserving surgery (lumpectomy) with whole-breast radiation therapy, or mastectomy with or without reconstruction 5, 6
• The National Comprehensive Cancer Network recommends mastectomy with or without reconstruction as an option for patients with early/operable locoregional disease 2

Adjuvant Systemic Therapy Decision Algorithm

• For hormone receptor-positive (ER+ and/or PR+), HER2-negative disease, the National Comprehensive Cancer Network suggests administering adjuvant endocrine therapy for 5-10 years 9
• Postmenopausal women: aromatase inhibitors (anastrozole, letrozole, exemestane) are superior to tamoxifen for response and time to progression, as stated by the European Society for Medical Oncology 7

Stage IV: Metastatic/Recurrent Disease

• The European Society for Medical Oncology recommends obtaining histopathological or cytopathological confirmation of metastatic disease whenever possible 7
• Reassess ER/PR/HER2 status on metastatic lesions, as receptor status can change from primary tumor, as suggested by the National Comprehensive Cancer Network 7, 9

Systemic Therapy Algorithm

• For hormone receptor-positive, HER2-negative metastatic disease, the European Society for Medical Oncology recommends first-line: third-generation aromatase inhibitors (anastrozole, letrozole, exemestane) OR tamoxifen for postmenopausal patients 7
• For HER2-positive metastatic disease, the National Comprehensive Cancer Network suggests combining HER2-directed therapy (trastuzumab) with chemotherapy 9

Critical Pathology Requirements Across All Stages

• The College of American Pathologists recommends using standardized reporting protocols for all breast specimens 1, 2
• Mandatory biomarker testing: ER, PR (by immunohistochemistry), and HER2 status, as stated by the American Cancer Society 6, 3